Therapeutic targeting of fibrotic epithelial-mesenchymal transition–an outstanding challenge

A. Fintha, Ákos Gasparics, L. Rosivall, Attila Sebe

Research output: Contribution to journalArticle

Abstract

Back in 1995, a landmark paper was published, which shaped the fibrosis literature for many years to come. During the characterization of a fibroblast-specific marker (FSP1) in the kidneys, an observation was made, which gave rise to the hypothesis that “fibroblasts in some cases arise from the local conversion of epithelium.” In the following years, epithelial-mesenchymal transition was in the spotlight of fibrosis research, especially in the kidney. However, the hypothesis came under scrutiny following some discouraging findings from lineage tracing experiments and clinical observations. In this review, we provide a timely overview of the current position of the epithelial-mesenchymal transition hypothesis in the context of fibrosis (with a certain focus on renal fibrosis) and highlight some of the potential hurdles and pitfalls preventing therapeutic breakthroughs targeting fibrotic epithelial-mesenchymal transition.

Original languageEnglish
Article number388
JournalFrontiers in Pharmacology
Volume10
Issue numberMAR
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Epithelial-Mesenchymal Transition
Fibrosis
Kidney
Fibroblasts
Therapeutics
Epithelium
Observation
Research

Keywords

  • Chronic injury
  • Epithelial to mesenchymal transition
  • Fibrosis
  • Myofibroblast
  • Repair

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Therapeutic targeting of fibrotic epithelial-mesenchymal transition–an outstanding challenge. / Fintha, A.; Gasparics, Ákos; Rosivall, L.; Sebe, Attila.

In: Frontiers in Pharmacology, Vol. 10, No. MAR, 388, 01.01.2019.

Research output: Contribution to journalArticle

@article{17d39fb6c62a4168abb33e778d0abe3f,
title = "Therapeutic targeting of fibrotic epithelial-mesenchymal transition–an outstanding challenge",
abstract = "Back in 1995, a landmark paper was published, which shaped the fibrosis literature for many years to come. During the characterization of a fibroblast-specific marker (FSP1) in the kidneys, an observation was made, which gave rise to the hypothesis that “fibroblasts in some cases arise from the local conversion of epithelium.” In the following years, epithelial-mesenchymal transition was in the spotlight of fibrosis research, especially in the kidney. However, the hypothesis came under scrutiny following some discouraging findings from lineage tracing experiments and clinical observations. In this review, we provide a timely overview of the current position of the epithelial-mesenchymal transition hypothesis in the context of fibrosis (with a certain focus on renal fibrosis) and highlight some of the potential hurdles and pitfalls preventing therapeutic breakthroughs targeting fibrotic epithelial-mesenchymal transition.",
keywords = "Chronic injury, Epithelial to mesenchymal transition, Fibrosis, Myofibroblast, Repair",
author = "A. Fintha and {\'A}kos Gasparics and L. Rosivall and Attila Sebe",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fphar.2019.00388",
language = "English",
volume = "10",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "MAR",

}

TY - JOUR

T1 - Therapeutic targeting of fibrotic epithelial-mesenchymal transition–an outstanding challenge

AU - Fintha, A.

AU - Gasparics, Ákos

AU - Rosivall, L.

AU - Sebe, Attila

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Back in 1995, a landmark paper was published, which shaped the fibrosis literature for many years to come. During the characterization of a fibroblast-specific marker (FSP1) in the kidneys, an observation was made, which gave rise to the hypothesis that “fibroblasts in some cases arise from the local conversion of epithelium.” In the following years, epithelial-mesenchymal transition was in the spotlight of fibrosis research, especially in the kidney. However, the hypothesis came under scrutiny following some discouraging findings from lineage tracing experiments and clinical observations. In this review, we provide a timely overview of the current position of the epithelial-mesenchymal transition hypothesis in the context of fibrosis (with a certain focus on renal fibrosis) and highlight some of the potential hurdles and pitfalls preventing therapeutic breakthroughs targeting fibrotic epithelial-mesenchymal transition.

AB - Back in 1995, a landmark paper was published, which shaped the fibrosis literature for many years to come. During the characterization of a fibroblast-specific marker (FSP1) in the kidneys, an observation was made, which gave rise to the hypothesis that “fibroblasts in some cases arise from the local conversion of epithelium.” In the following years, epithelial-mesenchymal transition was in the spotlight of fibrosis research, especially in the kidney. However, the hypothesis came under scrutiny following some discouraging findings from lineage tracing experiments and clinical observations. In this review, we provide a timely overview of the current position of the epithelial-mesenchymal transition hypothesis in the context of fibrosis (with a certain focus on renal fibrosis) and highlight some of the potential hurdles and pitfalls preventing therapeutic breakthroughs targeting fibrotic epithelial-mesenchymal transition.

KW - Chronic injury

KW - Epithelial to mesenchymal transition

KW - Fibrosis

KW - Myofibroblast

KW - Repair

UR - http://www.scopus.com/inward/record.url?scp=85066462652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066462652&partnerID=8YFLogxK

U2 - 10.3389/fphar.2019.00388

DO - 10.3389/fphar.2019.00388

M3 - Article

VL - 10

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - MAR

M1 - 388

ER -